Compare CMDB & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMDB | CAPR |
|---|---|---|
| Founded | 2023 | 2005 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.2M | 584.9M |
| IPO Year | 2024 | 2011 |
| Metric | CMDB | CAPR |
|---|---|---|
| Price | $20.46 | $7.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 51.3K | ★ 2.5M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.29 | $2.96 |
| 52 Week High | $24.76 | $40.37 |
| Indicator | CMDB | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.94 | 40.60 |
| Support Level | $16.35 | $7.37 |
| Resistance Level | $23.16 | $10.12 |
| Average True Range (ATR) | 0.93 | 0.55 |
| MACD | -0.34 | -0.10 |
| Stochastic Oscillator | 14.55 | 2.66 |
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing transportation of dry bulk commodities globally for a broad range of customers. Its vessels transport a broad range of bulks, such as iron ore, coal and grains and minor bulks, such as bauxite, phosphate fertilizers and steel products, across shipping routes globally. The company's vessel fleet includes Current Dry Bulk Fleet, Chartered-In Vessels Fleet, and Chartered-In Newbuilding Vessels. It operates under one reportable segment, that of operating dry bulk vessels.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.